查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587468

抗心律不整藥物市場規模、佔有率和趨勢分析報告：按藥物類別、給藥途徑、分銷管道、地區和細分市場預測，2024-2030年

Antiarrhythmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Beta Blockers, Sodium Channel Blockers), By Route of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

抗心律不整藥物市場成長與趨勢：

Grand View Research研究報告顯示，預計到2030年，全球抗心律不整藥物市場規模將達16.2億美元，2024年至2030年複合年成長率為6.4%。

根據世界衛生組織 (WHO) 的數據，CVD 是全球第一大死因，每年導致約 1,790 萬人死亡。

此外，人口老化也是市場擴張的主要因素。美國人口普查局報告稱，到 2030 年，大約 20% 的美國人口將達到 65 歲或以上。這種人口結構的變化預計將導致心血管疾病（包括心律不整）的增加，以及抗心律不整藥物的需求增加。隨著年齡的成長，心臟病的風險會增加，需要持續的治療和管理策略。這種趨勢並非美國獨有；許多已開發國家和開發中國家也出現了類似的人口變化，導致全球抗心律不整藥物的需求增加。

最近的藥物開發趨勢進一步推動了市場成長。抗心律不整藥物領域的研究和創新導致了新化合物和治療方法的引入。例如，針對特定離子通道的新藥物配方的開發提高了這些藥物的功效和安全性。此外，個人化醫療和藥物基因組學的進步為客製化治療策略鋪平了道路，這些策略可以根據個別患者的情況最佳化藥物療效。這些創新不僅改善了治療結果，還促進了醫療保健專業人員採用抗心律不整療法。

抗心律不整藥物市場報告亮點

  • 按藥物類別分類， BETA阻斷劑細分市場在 2023 年佔據最大銷售佔有率，達到 34.7%。由於它能有效降低心率和控制血壓，因此已成為治療這些疾病的基石。
  • 依給藥途徑，口服製劑佔最大銷售佔有率，2023年約65.0%。口服製劑在治療心房顫動和心室心搏過速等慢性疾病方面特別有吸引力，因為它們允許患者家用中自行進行治療，無需進行侵入性手術或去醫院就診。
  • 從分銷管道來看，2023年醫院藥局將佔據全球抗心律不整藥物市場的最大銷售佔有率，約佔55.0%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章抗心律不整藥物市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 抗心律不整藥物市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章 抗心律不整藥物市場：藥物類別估計與趨勢分析

  • 抗心律不整藥物市場：藥物類別儀表板
  • 抗心律不整藥物市場：藥品類別波動分析
  • 抗心律不整藥物市場：按藥物類別分類的收益
  • 鈉通道阻斷劑
  • 鉀通道阻斷劑
  • 鈣離子通道阻斷劑
  • 其他

第5章 抗心律不整藥物市場：給藥途徑估算與趨勢分析

  • 抗心律不整藥物市場：給藥途徑儀表板
  • 抗心律不整藥物市場：給藥途徑變異分析
  • 按途徑的收益
  • 口服
  • 胃腸外的
  • 其他

第6章 抗心律不整藥物市場：通路估算及趨勢分析

  • 抗心律不整藥物市場：通路儀表板
  • 按分銷管道分類的收益
  • 醫院藥房
  • 零售藥房
  • 其他

第7章 抗心律不整藥物市場：按藥物類別分類的區域估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • 2023年主要企業市場佔有率分析
    • Pfizer
    • Novartis
    • Mylan
    • Baxter International
    • Sanofi
    • GlaxoSmithKline
    • Mayne Pharma
    • Upsher-Smith Laboratories
    • Amomed Pharma
    • Merck
Product Code: GVR-4-68040-479-7

Antiarrhythmic Drugs Market Growth & Trends:

The global antiarrhythmic drugs market size is anticipated to reach USD 1.62 billion by 2030, growing at a CAGR of 6.4% from 2024 to 2030, according to a report by Grand View Research, Inc. This anticipated growth is driven by multiple interrelated factors, including the rising prevalence of cardiovascular diseases (CVDs), an aging global population, advancements in drug development, regulatory support, and government initiatives aimed at improving cardiovascular health.According to the World Health Organization (WHO), CVDs are the leading cause of death globally, responsible for approximately 17.9 million deaths annually.

Furthermore, the aging population is a significant factor contributing to market expansion. The U.S. Census Bureau reports that by 2030, approximately 20% of the U.S. population will be 65 years or older. This demographic shift is expected to lead to an increase in cardiovascular conditions, including arrhythmias, thereby heightening the demand for antiarrhythmic drugs. As people age, their risk of developing heart conditions increases, necessitating ongoing treatment and management strategies. This trend is not limited to the U.S.; many developed and developing nations are experiencing similar demographic changes, resulting in a global increase in demand for antiarrhythmic therapies.

Recent advancements in drug development are further propelling market growth. Research and innovation in the field of antiarrhythmic drugs have led to the introduction of novel compounds and therapeutic approaches. For instance, the development of new drug formulations that target specific ion channels has improved the efficacy and safety profiles of these medications. Moreover, advances in personalized medicine and pharmacogenomics are paving the way for tailored treatment strategies that optimize drug efficacy based on individual patient profiles. Such innovations not only enhance treatment outcomes but also encourage the adoption of antiarrhythmic therapies among healthcare providers.

Antiarrhythmic Drugs Market Report Highlights:

  • By drug class, the beta blockers segment accounted for the largest revenue share of 34.7% in 2023. Their efficacy in reducing heart rate and controlling blood pressure has made them a cornerstone in the treatment of these disorders.
  • Based on route of administration, the oral segment accounted for the largest revenue share of around 65.0% in 2023. Oral formulations allow patients to self-administer treatments at home, eliminating the need for invasive procedures or hospital visits, which can be particularly appealing in managing chronic conditions such as atrial fibrillation and ventricular tachycardia.
  • Based on distribution channels, the hospital pharmacies segment accounted for the largest revenue share of around 55.0% in global market for antiarrhythmic drugs in 2023.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug Class Outlook
    • 2.2.2. Route of Administration
    • 2.2.3. Distribution Channel
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antiarrhythmic Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising Prevalence of Cardiovascular Diseases
      • 3.2.1.2. Advancements in Drug Development
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High Drug Class Cost
      • 3.2.2.2. Competition from Alternative Therapies
  • 3.3. Antiarrhythmic Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Antiarrhythmic Drugs Market: Drug Class Estimates & Trend Analysis

  • 4.1. Antiarrhythmic Drugs Market: Drug Class Dashboard
  • 4.2. Antiarrhythmic Drugs Market: Drug Class Movement Analysis
  • 4.3. Antiarrhythmic Drugs Market by Drug Class, Revenue
  • 4.4. Sodium Channel Blockers
    • 4.4.1. Sodium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Potassium Channel Blockers
    • 4.5.1. Potassium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Calcium Channel Blockers
    • 4.6.1. Calcium Channel Blockers market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antiarrhythmic Drugs Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Antiarrhythmic Drugs Market: Route of Administration Dashboard
  • 5.2. Antiarrhythmic Drugs Market: Route of Administration Movement Analysis
  • 5.3. Antiarrhythmic Drugs Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Parenteral
    • 5.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Antiarrhythmic Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Antiarrhythmic Drugs Market: Distribution Channel Dashboard
  • 6.2. Antiarrhythmic Drugs Market Estimates and Forecasts, By Distribution Channel, Revenue (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Other
    • 6.5.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Antiarrhythmic Drugs Market: Regional Estimates & Trend Analysis by Drug Class, Route of Administration, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key company market share analysis, 2023
    • 8.2.3. Pfizer
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Novartis
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Mylan
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Baxter International
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. Sanofi
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. GlaxoSmithKline
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Mayne Pharma
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Upsher-Smith Laboratories
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. Amomed Pharma
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Merck
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List Of Abbreviation
  • Table 2 North America Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 3 North America Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 4 North America Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 5 North America Antiarrhythmic Drugs Market, Distribution Channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 7 U.S. Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 9 Canada Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 10 Canada Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 11 Canada Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 13 Mexico Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 14 Mexico Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 16 Europe Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 17 Europe Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Europe Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 20 Germany Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 21 Germany Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 UK Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 23 UK Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 UK Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 France Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 26 France Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 France Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 29 Italy Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 Italy Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 32 Spain Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 33 Spain Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 35 Denmark Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 Denmark Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 38 Sweden Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 Sweden Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 Norway Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 41 Norway Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 Norway Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 47 China Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 48 China Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 China Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 50 Japan Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 51 Japan Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Japan Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 53 India Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 54 India Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 India Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 57 South Korea Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 South Korea Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Australia Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 60 Australia Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Australia Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 62 Thailand Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 63 Thailand Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 Thailand Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 65 Latin America Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 66 Latin America Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 67 Latin America Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 68 Latin America Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Brazil Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 70 Brazil Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 71 Brazil Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 73 Argentina Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 74 Argentina Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 75 MEA Antiarrhythmic Drugs Market, By Region, 2018 - 2030 (USD Million)
  • Table 76 MEA Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 77 MEA Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 78 MEA Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 80 South Africa Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 81 South Africa Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 85 UAE Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 86 UAE Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 87 UAE Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Antiarrhythmic Drugs Market, By Drug Class, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Antiarrhythmic Drugs Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Antiarrhythmic Drugs Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Antiarrhythmic Drugs Market: Market Outlook
  • Fig. 14 Antiarrhythmic Drugs Competitive Insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Antiarrhythmic Drugs Market Driver Impact
  • Fig. 18 Antiarrhythmic Drugs Market Restraint Impact
  • Fig. 19 Antiarrhythmic Drugs Market Strategic Initiatives Analysis
  • Fig. 20 Antiarrhythmic Drugs Market: Drug Class Movement Analysis
  • Fig. 21 Antiarrhythmic Drugs Market: Drug Class Outlook And Key Takeaways
  • Fig. 22 Sodium Channel Blockers market estimates and forecast, 2018 - 2030
  • Fig. 23 Beta Blockers market estimates and forecast, 2018 - 2030
  • Fig. 24 Potassium Channel Blockers market estimates and forecast, 2018 - 2030
  • Fig. 25 Calcium Channel Blockers market estimates and forecast, 2018 - 2030
  • Fig. 26 Other market estimates and forecast, 2018 - 2030
  • Fig. 27 Antiarrhythmic Drugs Market: Route of Administration Movement Analysis
  • Fig. 28 Antiarrhythmic Drugs Market: Route of Administration Outlook And Key Takeaways
  • Fig. 29 Oral market estimates and forecast, 2018 - 2030
  • Fig. 30 Parenteral market estimates and forecast, 2018 - 2030
  • Fig. 31 Other market estimates and forecast, 2018 - 2030
  • Fig. 32 Antiarrhythmic Drugs Market: Distribution Channel Movement Analysis
  • Fig. 33 Antiarrhythmic Drugs Market: Distribution Channel Outlook And Key Takeaways
  • Fig. 34 Hospital Pharmacies market estimates and forecast, 2018 - 2030
  • Fig. 35 Retail Pharmacies market estimates and forecast, 2018 - 2030
  • Fig. 36 Other market estimates and forecast, 2018 - 2030
  • Fig. 37 Antiarrhythmic Drugs Market: Regional Movement Analysis
  • Fig. 38 Antiarrhythmic Drugs Market: Regional Outlook And Key Takeaways
  • Fig. 39 Antiarrhythmic Drugs market share and leading players
  • Fig. 40 North America, by country
  • Fig. 41 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. key country dynamics
  • Fig. 43 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Canada key country dynamics
  • Fig. 45 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Mexico key country dynamics
  • Fig. 47 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 UK key country dynamics
  • Fig. 50 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Germany key country dynamics
  • Fig. 52 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 France key country dynamics
  • Fig. 54 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Italy key country dynamics
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Spain key country dynamics
  • Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Denmark key country dynamics
  • Fig. 60 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Sweden key country dynamics
  • Fig. 62 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Norway key country dynamics
  • Fig. 64 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 China key country dynamics
  • Fig. 67 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Japan key country dynamics
  • Fig. 69 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 India key country dynamics
  • Fig. 71 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Thailand key country dynamics
  • Fig. 73 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 South Korea key country dynamics
  • Fig. 75 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Australia key country dynamics
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Brazil key country dynamics
  • Fig. 80 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Argentina key country dynamics
  • Fig. 82 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 South Africa key country dynamics
  • Fig. 85 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Saudi Arabia key country dynamics
  • Fig. 87 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 UAE key country dynamics
  • Fig. 89 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Kuwait key country dynamics
  • Fig. 91 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Market share of key market players- Antiarrhythmic Drugs market